OKYO OKYO Pharma Limited
HealthcareAs of 2026-05-26
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
-17.86
P/S
0.00
EV/EBITDA
-6.10
DCF Value
$-0.11
FCF Yield
-5.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
102.9%
ROA
-99.3%
ROIC
154.2%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 null | $0.00 | $-2.6M | $— |
| Q4 null | $0.00 | $-2.0M | $— |
| FY null | $0.00 | $-4.7M | $— |
| Q2 null | $0.00 | $-2.7M | $— |
Analyst Ratings
View AllConsensus
Buy
Target (Consensus)
$7.00
Target (Median)
$7.00
Target Range
$7.00 - $7.00
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
Biotechnology
Country
GB
Exchange
—
Beta
-0.05
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.